Want to see HK:2511 full AI Analyst Report?
Top Page
Hightide Therapeutics Inc
(2511)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$3.00
▼(-1.64% Downside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite balance-sheet improvement). Technicals are a meaningful offset, with price strength above major moving averages and positive momentum indicators. Valuation provides limited support due to a negative P/E and no dividend yield.
Positive Factors
Balance-sheet repair
The return to positive equity and more manageable leverage materially improves financial resilience compared with 2021–2022. Although funding risk remains, a stronger capital structure gives Hightide greater flexibility to support research activities and manage ongoing losses.
Negative Factors
No reported revenue
Zero reported revenue indicates that Hightide has not yet established a commercial revenue base, leaving the business dependent on future development and commercialization of therapeutic candidates. This limits operating leverage and makes financial progress difficult to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet repair
The return to positive equity and more manageable leverage materially improves financial resilience compared with 2021–2022. Although funding risk remains, a stronger capital structure gives Hightide greater flexibility to support research activities and manage ongoing losses.
Read all positive factors
Hightide Therapeutics Inc (2511) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.79B
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth14.40%
CountryHK
Employees51
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.52
Shares Outstanding571,325,700
10 Day Avg. Volume550,350
30 Day Avg. Volume1,054,988
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Hightide Therapeutics Inc Business Overview & Revenue Model
Company Description
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle met...
Hightide Therapeutics Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -222.16M | -443.75M | -447.70M | -225.68M | -131.80M |
| Net Income | -244.97M | -381.79M | -939.31M | -190.24M | -221.15M |
Balance Sheet | |||||
| Total Assets | 551.58M | 559.93M | 795.04M | 855.82M | 777.23M |
| Cash, Cash Equivalents and Short-Term Investments | 502.94M | 490.52M | 735.70M | 828.33M | 763.91M |
| Total Debt | 126.92M | 77.91M | 16.43M | 1.27B | 1.01B |
| Total Liabilities | 186.75M | 135.76M | 92.26M | 1.33B | 1.05B |
| Stockholders Equity | 307.14M | 424.17M | 702.77M | -470.53M | -271.77M |
Cash Flow | |||||
| Free Cash Flow | -166.98M | -299.46M | -368.56M | -172.90M | -90.12M |
| Operating Cash Flow | -166.91M | -294.81M | -367.67M | -172.71M | -88.40M |
| Investing Cash Flow | -102.90M | -89.72M | 321.64M | -415.66M | 1.59M |
| Financing Cash Flow | 199.72M | 54.79M | 399.46M | 46.03M | 493.98M |
Hightide Therapeutics Inc Technical Analysis
Positive
3.05
Price Trends
3.02
Positive
3.19
Positive
3.03
Positive
Market Momentum
0.09
Negative
53.67
Neutral
60.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2511, the sentiment is Positive. The current price of 3.05 is below the 20-day moving average (MA) of 3.27, above the 50-day MA of 3.02, and above the 200-day MA of 3.03, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 53.67 is Neutral, neither overbought nor oversold. The STOCH value of 60.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2511.
Hightide Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$1.79B | -5.30 | -114.28% | ― | ― | 14.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$1.86B | 18.12 | 48.25% | ― | 88.38% | ― | |
46 Neutral | HK$1.49B | -7.09 | -41.81% | ― | ― | -4.24% | |
43 Neutral | HK$378.56M | -1.62 | -32.08% | ― | 215.14% | 40.49% | |
43 Neutral | HK$599.25M | -1.73 | -35.24% | ― | 35.47% | 46.42% | |
42 Neutral | HK$1.12B | 34.22 | -3.95% | ― | -8.00% | 51.26% |
* Healthcare Sector Average
HK:2511
Hightide Therapeutics Inc
3.35
-1.02
-23.34%
HK:1228
CANbridge Pharmaceuticals Inc.
1.90
-0.92
-32.62%
HK:2181
Mabpharm Limited
0.44
-0.37
-45.63%
HK:3681
SinoMab Bioscience Ltd.
1.10
-0.81
-42.41%
HK:6628
Transcenta Holding Limited
0.91
-3.64
-80.00%
HK:2487
Cutia Therapeutics
1.60
-8.53
-84.21%
Hightide Therapeutics Inc Corporate Events
HighTide Therapeutics Grants Performance-Linked Share Options and Awards
Sep 1, 2026
HighTide Therapeutics has granted 2,040,450 share options and 306,749 share awards under its 2025 Share Incentive Plan, representing about 0.30% and 0.05% of its outstanding share capital, respectively. The grants include a significant allocation ...
HighTide Therapeutics Highlights HTD1801 as Foundational CKM Therapy in Interim Results
Aug 31, 2026
HighTide Therapeutics has reported its unaudited interim results for the six months ended June 30, 2026, alongside comparative figures for the prior year period, underscoring ongoing investment in its cardiovascular-kidney-metabolic disease pipeli...
HighTide Therapeutics Sets Board Meeting to Approve Interim Results
Aug 14, 2026
HighTide Therapeutics Inc. has scheduled a board meeting for August 31, 2026, to review and approve the interim results for the six months ended June 30, 2026. The board will also address other corporate matters, signaling the forthcoming release ...
HighTide Therapeutics Raises HK$225 Million Through Share Placing to Fund HTD1801 Expansion
Aug 7, 2026
HighTide Therapeutics has completed a placing of 98,710,000 new shares under its general mandate, raising approximately HK$225.1 million in gross proceeds at HK$2.28 per share through at least six independent investors. The transaction, which clos...
HighTide Therapeutics Launches Discounted Share Placing to Raise HK$225 Million
Jul 31, 2026
HighTide Therapeutics, Inc. has entered into a placing agreement with a sole placing agent to issue up to 99,000,000 new shares at HK$2.28 each to at least six independent investors. The placing shares represent about 17.33% of the existing share ...
HighTide Therapeutics advances HTD1801 commercialization after NEJM Evidence recognition
Jul 10, 2026
HighTide Therapeutics reported that Phase III study results for its core product HTD1801 in combination with metformin for type 2 diabetes were recently published in NEJM Evidence, a sub-journal of The New England Journal of Medicine. An accompany...
HighTide Therapeutics Terminates Connected Loan After Regulatory Scrutiny
Jul 2, 2026
HighTide Therapeutics Inc., a pre-revenue biotech company listed on the Hong Kong Stock Exchange, primarily focuses on developing new therapeutic products rather than engaging in financial services. Its status as a non-lending, early-stage life sc...
HighTide Therapeutics Wins Strong Shareholder Backing at 2026 AGM
Jun 29, 2026
HighTide Therapeutics, Inc. reported that all resolutions at its annual general meeting on June 29, 2026, were approved by shareholders through poll voting. Investors endorsed the adoption of the 2025 audited financial statements, the re-election ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.